Gossamer Bio Q1 net loss widens on higher R&D expenses

Gossamer Bio

18/05/2026 12:09

Overview

US biopharma developer's Q1 revenue from collaborators rose yr/yr, driven by seralutinib program

Net loss for Q1 widened, reflecting increased R&D and one-time G&A expenses

Company launched exchange offer for convertible notes to reduce debt and strengthen balance sheet

Outlook

Company expects to submit NDA for seralutinib in pulmonary arterial hypertension (PAH) in September 2026

If NDA is accepted, seralutinib could be eligible for FDA approval in Q3 2027

Gossamer expects current cash to fund operations into Q1 2027

Result Drivers

SERALUTINIB PROGRAM - Increased Q1 revenue from collaborators was driven by activity in the seralutinib program

CLINICAL TRIAL COSTS - Higher R&D expenses in Q1 were primarily due to costs associated with clinical trials for seralutinib

ONE-TIME SEVERANCE CHARGES - Increased G&A expenses were mainly due to one-time severance and related charges from a reduction in force

Company press release: ID:nBw3YQj50a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.20
Q1 Net Income
-$46.66 mln
Q1 Basic EPS
-$0.20
Q1 Operating Expenses
$61.82 mln
Q1 Operating Income
-$44.87 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Gossamer Bio Inc is $1.00, about 194.1% above its May 15 closing price of $0.34

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)